Cancer metabolism: a therapeutic perspective (original) (raw)

• Ahn, C. S. & Metallo, C. M. Mitochondria as biosynthetic factories for cancer proliferation. Cancer Metab. 3, 1 (2015).
  PubMed PubMed Central Google Scholar
• Vander Heiden, M. G., Cantley, L. C. & Thompson, C. B. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324, 1029–1033 (2009).
  CAS PubMed PubMed Central Google Scholar
• Pfeiffer, T., Schuster, S. & Bonhoeffer, S. Cooperation and competition in the evolution of ATP-producing pathways. Science 292, 504–507 (2001).
  CAS PubMed Google Scholar
• Cox, E. & Bonner, J. The advantages of togetherness. Science 292, 448–449 (2001).
  CAS PubMed Google Scholar
• Zu, X. L. & Guppy, M. Cancer metabolism: facts, fantasy, and fiction. Biochem. Biophys. Res. Commun. 313, 459–465 (2004).
  CAS PubMed Google Scholar
• Martinez-Outschoorn, U. E., Lisanti, M. P. & Sotgia, F. Catabolic cancer-associated fibroblasts transfer energy and biomass to anabolic cancer cells, fueling tumor growth. Semin. Cancer Biol. 25, 47–60 (2014).
  CAS PubMed Google Scholar
• Sonveaux, P. et al. Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J. Clin. Invest. 118, 3930–3942 (2008).
  CAS PubMed PubMed Central Google Scholar
• Whitaker-Menezes, D. et al. Hyperactivation of oxidative mitochondrial metabolism in epithelial cancer cells in situ: visualizing the therapeutic effects of metformin in tumor tissue. Cell Cycle 10, 4047–4064 (2011).
  CAS PubMed PubMed Central Google Scholar
• Goodwin, M. L. et al. Modeling alveolar soft part sarcomagenesis in the mouse: a role for lactate in the tumor microenvironment. Cancer Cell 26, 851–862 (2014).
  CAS PubMed PubMed Central Google Scholar
• Doherty, J. R. & Cleveland, J. L. Targeting lactate metabolism for cancer therapeutics. J. Clin. Invest. 123, 3685–3692 (2013).
  CAS PubMed PubMed Central Google Scholar
• Pietrocola, F., Galluzzi, L., Bravo- San Pedro, J. M., Madeo, F. & Kroemer, G. Acetyl coenzyme A: a central metabolite and second messenger. Cell Metab. 21, 805–821 (2015).
  CAS PubMed Google Scholar
• Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646–674 (2011).
  CAS PubMed Google Scholar
• Viale, A. et al. Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. Nature 514, 628–632 (2014).
  CAS PubMed PubMed Central Google Scholar
• Wallace, D. C. Mitochondria and cancer Nat. Rev.Cancer 12, 685–698 (2012).
  CAS PubMed PubMed Central Google Scholar
• Pavlides, S. et al. The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor stroma. Cell Cycle 8, 3984–4001 (2009).
  CAS PubMed Google Scholar
• Nieman, K. M. et al. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat. Med. 17, 1498–1503 (2011).
  CAS PubMed PubMed Central Google Scholar
• Fiaschi, T. et al. Reciprocal metabolic reprogramming through lactate shuttle coordinately influences tumor–stroma interplay. Cancer Res. 72, 5130–5140 (2012).
  CAS PubMed Google Scholar
• Boroughs, L. K. & DeBerardinis, R. J. Metabolic pathways promoting cancer cell survival and growth. Nat. Cell Biol. 17, 351–359 (2015).
  CAS PubMed PubMed Central Google Scholar
• Galluzzi, L., Kepp, O., Vander Heiden, M. G. & Kroemer, G. Metabolic targets for cancer therapy. Nat. Rev. Drug Discov. 12, 829–846 (2013).
  CAS PubMed Google Scholar
• Marchiq, I. & Pouyssegur, J. Hypoxia, cancer metabolism and the therapeutic benefit of targeting lactate/H+ symporters. J. Mol. Med. (Berl.) 94, 155–171 (2016).
  CAS Google Scholar
• Deep, G. & Agarwal, R. Targeting tumor microenvironment with silibinin: promise and potential for a translational cancer chemopreventive strategy. Curr. Cancer Drug Targets 13, 486–499 (2013).
  CAS PubMed PubMed Central Google Scholar
• Ooi, A. T. & Gomperts, B. N. Molecular pathways: targeting cellular energy metabolism in cancer via inhibition of SLC2A1 and LDHA. Clin. Cancer Res. 21, 2440–2444 (2015).
  CAS PubMed PubMed Central Google Scholar
• Vander Heiden, M. G. et al. Identification of small molecule inhibitors of pyruvate kinase M2. Biochem. Pharmacol. 79, 1118–1124 (2010).
  CAS PubMed Google Scholar
• Cortes-Cros, M. et al. M2 isoform of pyruvate kinase is dispensable for tumor maintenance and growth. Proc. Natl Acad. Sci. USA 110, 489–494 (2013).
  CAS PubMed Google Scholar
• Maschek, G. et al. 2-deoxy-d-glucose increases the efficacy of adriamycin and paclitaxel in human osteosarcoma and non-small cell lung cancers in vivo. Cancer Res. 64, 31–34 (2004).
  CAS PubMed Google Scholar
• Goldin, N. et al. Methyl jasmonate binds to and detaches mitochondria-bound hexokinase. Oncogene 27, 4636–4643 (2008).
  CAS PubMed Google Scholar
• Dwarakanath, B. S. et al. Clinical studies for improving radiotherapy with 2-deoxy-D-glucose: present status and future prospects. J. Cancer Res. Ther. 5 (Suppl. 1), S21–S26 (2009).
  CAS PubMed Google Scholar
• Papaldo, P. et al. Addition of either lonidamine or granulocyte colony-stimulating factor does not improve survival in early breast cancer patients treated with high-dose epirubicin and cyclophosphamide. J. Clin. Oncol. 21, 3462–3468 (2003).
  CAS PubMed Google Scholar
• DeBerardinis, R. J. & Cheng, T. Q's next: the diverse functions of glutamine in metabolism, cell biology and cancer. Oncogene 29, 313–324 (2009).
  PubMed PubMed Central Google Scholar
• Marin-Valencia, I. et al. Analysis of tumor metabolism reveals mitochondrial glucose oxidation in genetically diverse human glioblastomas in the mouse brain in vivo. Cell Metab. 15, 827–837 (2012).
  CAS PubMed PubMed Central Google Scholar
• Lai, H. S., Lee, J. C., Lee, P. H., Wang, S. T. & Chen, W. J. Plasma free amino acid profile in cancer patients. Semin. Cancer Biol. 15, 267–276 (2005).
  CAS PubMed Google Scholar
• Fan, J. et al. Glutamine-driven oxidative phosphorylation is a major ATP source in transformed mammalian cells in both normoxia and hypoxia. Mol. Syst. Biol. 9, 712 (2013).
  CAS PubMed PubMed Central Google Scholar
• Metallo, C. M. et al. Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia. Nature 481, 380–384 (2011).
  PubMed PubMed Central Google Scholar
• Hensley, C. T., Wasti, A. T. & DeBerardinis, R. J. Glutamine and cancer: cell biology, physiology, and clinical opportunities. J. Clin. Invest. 123, 3678–3684 (2013).
  CAS PubMed PubMed Central Google Scholar
• Mullen, A. R. et al. Reductive carboxylation supports growth in tumour cells with defective mitochondria. Nature 481, 385–388 (2011).
  PubMed PubMed Central Google Scholar
• Diehn, M. et al. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 458, 780–783 (2009).
  CAS PubMed PubMed Central Google Scholar
• Xiang, Y. et al. Targeted inhibition of tumor-specific glutaminase diminishes cell-autonomous tumorigenesis. J. Clin. Invest. 125, 2293–2306 (2015).
  PubMed PubMed Central Google Scholar
• Gross, M. I. et al. Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer. Mol. Cancer Ther. 13, 890–901 (2014).
  CAS PubMed Google Scholar
• Weinberg, F. et al. Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. Proc. Natl Acad. Sci. USA 107, 8788–8793 (2010).
  CAS PubMed PubMed Central Google Scholar
• Filipp, F. V. et al. Glutamine-fueled mitochondrial metabolism is decoupled from glycolysis in melanoma. Pigment Cell Melanoma Res. 25, 732–739 (2012).
  CAS PubMed PubMed Central Google Scholar
• Hirayama, A. et al. Quantitative metabolome profiling of colon and stomach cancer microenvironment by capillary electrophoresis time-of-flight mass spectrometry. Cancer Res. 69, 4918–4925 (2009).
  CAS PubMed Google Scholar
• Ogawa, T., Washio, J., Takahashi, T., Echigo, S. & Takahashi, N. Glucose and glutamine metabolism in oral squamous cell carcinoma: insight from a quantitative metabolomic approach. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. 118, 218–225 (2014).
  PubMed Google Scholar
• Hirschhaeuser, F., Sattler, U. G. & Mueller-Klieser, W. Lactate: a metabolic key player in cancer. Cancer Res. 71, 6921–6925 (2011).
  CAS PubMed Google Scholar
• Kennedy, K. M. et al. Catabolism of exogenous lactate reveals it as a legitimate metabolic substrate in breast cancer. PLoS ONE 8, e75154 (2013).
  CAS PubMed PubMed Central Google Scholar
• Walenta, S., Schroeder, T. & Mueller-Klieser, W. Lactate in solid malignant tumors: potential basis of a metabolic classification in clinical oncology. Curr. Med. Chem. 11, 2195–2204 (2004).
  CAS PubMed Google Scholar
• Joyce, J. A. & Fearon, D. T. T cell exclusion, immune privilege, and the tumor microenvironment. Science 348, 74–80 (2015).
  CAS PubMed Google Scholar
• Colegio, O. R. et al. Functional polarization of tumour-associated macrophages by tumour-derived lactic acid. Nature 513, 559–563 (2013).
  Google Scholar
• Le, A. et al. Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proc. Natl Acad. Sci. USA 107, 2037–2042 (2010).
  CAS PubMed PubMed Central Google Scholar
• Doherty, J. R. et al. Blocking lactate export by inhibiting the Myc target MCT1 disables glycolysis and glutathione synthesis. Cancer Res. 74, 908–920 (2014).
  CAS PubMed Google Scholar
• Martinez-Outschoorn, U. E., Sotgia, F. & Lisanti, M. P. Power surge: supporting cells 'fuel' cancer cell mitochondria. Cell Metab. 15, 4–5 (2012).
  CAS PubMed Google Scholar
• Sotgia, F. et al. Caveolin-1 and cancer metabolism in the tumor microenvironment: markers, models, and mechanisms. Annu. Rev. Pathol. 7, 423–467 (2012).
  CAS PubMed Google Scholar
• Zhang, D. et al. Metabolic reprogramming of cancer-associated fibroblasts by IDH3α downregulation. Cell Rep. 10, 1335–1348 (2015).
  PubMed Google Scholar
• Polanski, R. et al. Activity of the monocarboxylate transporter 1 inhibitor AZD3965 in small cell lung cancer. Clin. Cancer Res. 20, 926–937 (2014).
  CAS PubMed Google Scholar
• Halestrap, A. P. Monocarboxylic acid transport. Compr. Physiol. 3, 1611–1643 (2013).
  PubMed Google Scholar
• Pellerin, L. & Magistretti, P. J. Sweet sixteen for ANLS. J. Cereb. Blood Flow Metab. 32, 1152–1166 (2012).
  CAS PubMed Google Scholar
• Scharfman, H. E. Metabolic control of epilepsy. Science 347, 1312–1313 (2015).
  CAS PubMed Google Scholar
• Sada, N., Lee, S., Katsu, T., Otsuki, T. & Inoue, T. Targeting LDH enzymes with a stiripentol analog to treat epilepsy. Science 347, 1362–1367 (2015).
  CAS PubMed Google Scholar
• Bailey, K. M., Wojtkowiak, J. W., Hashim, A. I. & Gillies, R. J. Targeting the metabolic microenvironment of tumors. Adv. Pharmacol. 65, 63–107 (2012).
  CAS PubMed PubMed Central Google Scholar
• Semenza, G. L. Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. Trends Pharmacol. Sci. 33, 207–214 (2012).
  CAS PubMed PubMed Central Google Scholar
• Rani, R. & Kumar, V. Recent update on human lactate dehydrogenase enzyme 5 (_h_LDH5) inhibitors: a promising approach for cancer chemotherapy. J. Med. Chem. 59, 487–496 (2016).
  CAS PubMed Google Scholar
• Kanno, T. et al. Lactate dehydrogenase M-subunit deficiency: a new type of hereditary exertional myopathy. Clin. Chim. Acta 173, 89–98 (1988).
  CAS PubMed Google Scholar
• Diers, A. R., Broniowska, K. A., Chang, C. F. & Hogg, N. Pyruvate fuels mitochondrial respiration and proliferation of breast cancer cells: effect of monocarboxylate transporter inhibition. Biochem. J. 444, 561–571 (2012).
  CAS PubMed Google Scholar
• Hatzivassiliou, G. et al. ATP citrate lyase inhibition can suppress tumor cell growth. Cancer Cell 8, 311–321 (2005).
  CAS PubMed Google Scholar
• Kamphorst, J. J. et al. Hypoxic and Ras-transformed cells support growth by scavenging unsaturated fatty acids from lysophospholipids. Proc. Natl Acad. Sci. USA 110, 8882–8887 (2013).
  CAS PubMed PubMed Central Google Scholar
• Gaglio, D. et al. Oncogenic K-Ras decouples glucose and glutamine metabolism to support cancer cell growth. Mol. Syst. Biol. 7, 523 (2011).
  PubMed PubMed Central Google Scholar
• Porstmann, T. et al. SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth. Cell Metab. 8, 224–236 (2008).
  CAS PubMed PubMed Central Google Scholar
• Duvel, K. et al. Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol. Cell 39, 171–183 (2010).
  PubMed PubMed Central Google Scholar
• Grassian, A. R., Metallo, C. M., Coloff, J. L., Stephanopoulos, G. & Brugge, J. S. Erk regulation of pyruvate dehydrogenase flux through PDK4 modulates cell proliferation. Genes Dev. 25, 1716–1733 (2011).
  CAS PubMed PubMed Central Google Scholar
• Schug, Z. T. et al. Acetyl-CoA synthetase 2 promotes acetate utilization and maintains cancer cell growth under metabolic stress. Cancer Cell 27, 57–71 (2015).
  CAS PubMed PubMed Central Google Scholar
• Rabinowitz, J. D. & White, E. Autophagy and metabolism. Science 330, 1344–1348 (2010).
  CAS PubMed PubMed Central Google Scholar
• Sun, Y. et al. Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B. Nat. Med. 18, 1359–1368 (2012).
  CAS PubMed PubMed Central Google Scholar
• Maslowski, K. M. et al. Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. Nature 461, 1282–1286 (2009).
  CAS PubMed PubMed Central Google Scholar
• Ley, R. E., Turnbaugh, P. J., Klein, S. & Gordon, J. I. Microbial ecology: human gut microbes associated with obesity. Nature 444, 1022–1023 (2006).
  CAS PubMed Google Scholar
• Clemente, J. C., Ursell, L. K., Parfrey, L. W. & Knight, R. The impact of the gut microbiota on human health: an integrative view. Cell 148, 1258–1270 (2012).
  CAS PubMed PubMed Central Google Scholar
• Abreu, M. T. & Peek, R. M. Jr. Gastrointestinal malignancy and the microbiome. Gastroenterology 146, 1534–1546.e1533 (2014).
  CAS PubMed Google Scholar
• Paoli, A., Bosco, G., Camporesi, E. M. & Mangar, D. Ketosis, ketogenic diet and food intake control: a complex relationship. Front. Psychol. 6, 27 (2015).
  PubMed PubMed Central Google Scholar
• Kruiswijk, F., Labuschagne, C. F. & Vousden, K. H. p53 in survival, death and metabolic health: a lifeguard with a licence to kill. Nat. Rev. Mol. Cell Biol. 16, 393–405 (2015).
  CAS PubMed Google Scholar
• Jeon, S. M., Chandel, N. S. & Hay, N. AMPK regulates NADPH homeostasis to promote tumour cell survival during energy stress. Nature 485, 661–665 (2012).
  CAS PubMed PubMed Central Google Scholar
• Parks, S. K., Mazure, N. M., Counillon, L. & Pouyssegur, J. Hypoxia promotes tumor cell survival in acidic conditions by preserving ATP levels. J. Cell. Physiol. 228, 1854–1862 (2013).
  CAS PubMed Google Scholar
• Caro, P. et al. Metabolic signatures uncover distinct targets in molecular subsets of diffuse large B cell lymphoma. Cancer Cell 22, 547–560 (2012).
  CAS PubMed PubMed Central Google Scholar
• Woyach, J. A. et al. Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib. N. Engl. J. Med. 370, 2286–2294 (2014).
  PubMed PubMed Central Google Scholar
• Pike, L. S., Smift, A. L., Croteau, N. J., Ferrick, D. A. & Wu, M. Inhibition of fatty acid oxidation by etomoxir impairs NADPH production and increases reactive oxygen species resulting in ATP depletion and cell death in human glioblastoma cells. Biochim. Biophys. Acta 1807, 726–734 (2011).
  CAS PubMed Google Scholar
• Schlaepfer, I. R. et al. Hypoxia induces triglycerides accumulation in prostate cancer cells and extracellular vesicles supporting growth and invasiveness following reoxygenation. Oncotarget 6, 22836–22856 (2015).
  PubMed PubMed Central Google Scholar
• Zaugg, K. et al. Carnitine palmitoyltransferase 1C promotes cell survival and tumor growth under conditions of metabolic stress. Genes Dev. 25, 1041–1051 (2011).
  CAS PubMed PubMed Central Google Scholar
• Holubarsch, C. J. et al. A double-blind randomized multicentre clinical trial to evaluate the efficacy and safety of two doses of etomoxir in comparison with placebo in patients with moderate congestive heart failure: the ERGO (etomoxir for the recovery of glucose oxidation) study. Clin. Sci. (Lond.) 113, 205–212 (2007).
  CAS Google Scholar
• Bertolini, F., Sukhatme, V. P. & Bouche, G. Drug repurposing in oncology — patient and health systems opportunities. Nat. Rev. Clin. Oncol. 12, 732–742 (2015).
  PubMed Google Scholar
• Hamanaka, R. B. & Chandel, N. S. Targeting glucose metabolism for cancer therapy. J. Exp. Med. 209, 211–215 (2012).
  CAS PubMed PubMed Central Google Scholar
• Wilson, P. M., Danenberg, P. V., Johnston, P. G., Lenz, H. J. & Ladner, R. D. Standing the test of time: targeting thymidylate biosynthesis in cancer therapy. Nat. Rev. Clin. Oncol. 11, 282–298 (2014).
  CAS PubMed Google Scholar
• Pieters, R. et al. Pharmacokinetics, pharmacodynamics, efficacy, and safety of a new recombinant asparaginase preparation in children with previously untreated acute lymphoblastic leukemia: a randomized phase 2 clinical trial. Blood 112, 4832–4838 (2008).
  CAS PubMed Google Scholar
• Ascierto, P. A. et al. Pegylated arginine deiminase treatment of patients with metastatic melanoma: results from phase I and II studies. J. Clin. Oncol. 23, 7660–7668 (2005).
  CAS PubMed Google Scholar
• Glazer, E. S. et al. Phase II study of pegylated arginine deiminase for nonresectable and metastatic hepatocellular carcinoma. J. Clin. Oncol. 28, 2220–2226 (2010).
  CAS PubMed Google Scholar
• Zhai, L. et al. Molecular pathways: targeting IDO1 and other tryptophan dioxygenases for cancer immunotherapy. Clin. Cancer Res. 21, 5427–5433 (2015).
  CAS PubMed PubMed Central Google Scholar
• Possemato, R. et al. Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. Nature 476, 346–350 (2011).
  CAS PubMed PubMed Central Google Scholar
• Locasale, J. W. et al. Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. Nat. Genet. 43, 869–874 (2011).
  CAS PubMed PubMed Central Google Scholar
• DeNicola, G. M. et al. NRF2 regulates serine biosynthesis in non-small cell lung cancer. Nat. Genet. 47, 1475–1481 (2015).
  CAS PubMed PubMed Central Google Scholar
• Li, B. & Simon, M. C. Molecular pathways: targeting MYC-induced metabolic reprogramming and oncogenic stress in cancer. Clin. Cancer Res. 19, 5835–5841 (2013).
  CAS PubMed Google Scholar
• Stine, Z. E., Walton, Z. E., Altman, B. J., Hsieh, A. L. & Dang, C. V. MYC, metabolism and cancer. Cancer Discov. 5, 1024–1039 (2015).
  CAS PubMed PubMed Central Google Scholar
• Fan, J. et al. Human phosphoglycerate dehydrogenase produces the oncometabolite d-2-hydroxyglutarate. ACS Chem. Biol. 10, 510–516 (2015).
  CAS PubMed Google Scholar
• Agrawal, S., Kumar, A., Srivastava, V. & Mishra, B. N. Cloning, expression, activity and folding studies of serine hydroxymethyltransferase: a target enzyme for cancer chemotherapy. J. Mol. Microbiol. Biotechnol. 6, 67–75 (2003).
  CAS PubMed Google Scholar
• Fan, J. et al. Quantitative flux analysis reveals folate-dependent NADPH production. Nature 510, 298–302 (2014).
  CAS PubMed PubMed Central Google Scholar
• Jain, M. et al. Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation. Science 336, 1040–1044 (2012).
  CAS PubMed PubMed Central Google Scholar
• Bauer, D. E., Hatzivassiliou, G., Zhao, F., Andreadis, C. & Thompson, C. B. ATP citrate lyase is an important component of cell growth and transformation. Oncogene 24, 6314–6322 (2005).
  CAS PubMed Google Scholar
• Chajes, V., Cambot, M., Moreau, K., Lenoir, G. M. & Joulin, V. Acetyl-CoA carboxylase α is essential to breast cancer cell survival. Cancer Res. 66, 5287–5294 (2006).
  CAS PubMed Google Scholar
• Clem, B. F. et al. A novel small molecule antagonist of choline kinase-alpha that simultaneously suppresses MAPK and PI3K/AKT signaling. Oncogene 30, 3370–3380 (2011).
  CAS PubMed PubMed Central Google Scholar
• Flavin, R., Peluso, S., Nguyen, P. L. & Loda, M. Fatty acid synthase as a potential therapeutic target in cancer. Future Oncol. 6, 551–562 (2010).
  CAS PubMed Google Scholar
• Mulvihill, M. M. & Nomura, D. K. Therapeutic potential of monoacylglycerol lipase inhibitors. Life Sci. 92, 492–497 (2013).
  CAS PubMed Google Scholar
• Gallego-Ortega, D., Gomez del Pulgar, T., Valdes-Mora, F., Cebrian, A. & Lacal, J. C. Involvement of human choline kinase alpha and beta in carcinogenesis: a different role in lipid metabolism and biological functions. Adv. Enzyme Regul. 51, 183–194 (2011).
  CAS PubMed Google Scholar
• Glunde, K., Bhujwalla, Z. M. & Ronen, S. M. Choline metabolism in malignant transformation. Nat. Rev. Cancer 11, 835–848 (2011).
  CAS PubMed PubMed Central Google Scholar
• Kubatka, P., Kruzliak, P., Rotrekl, V., Jelinkova, S. & Mladosievicova, B. Statins in oncological research: from experimental studies to clinical practice. Crit. Rev. Oncol. Hematol. 92, 296–311 (2014).
  PubMed Google Scholar
• Nielsen, S. F., Nordestgaard, B. G. & Bojesen, S. E. Statin use and reduced cancer-related mortality. N. Engl. J. Med. 367, 1792–1802 (2012).
  CAS PubMed Google Scholar
• Sriskanthadevan, S. et al. AML cells have low spare reserve capacity in their respiratory chain that renders them susceptible to oxidative metabolic stress. Blood 125, 2120–2130 (2015).
  CAS PubMed PubMed Central Google Scholar
• Funes, J. M. et al. Transformation of human mesenchymal stem cells increases their dependency on oxidative phosphorylation for energy production. Proc. Natl Acad. Sci. USA 104, 6223–6228 (2007).
  CAS PubMed PubMed Central Google Scholar
• Fogal, V. et al. Mitochondrial p32 protein is a critical regulator of tumor metabolism via maintenance of oxidative phosphorylation. Mol. Cell. Biol. 30, 1303–1318 (2010).
  CAS PubMed PubMed Central Google Scholar
• Curry, J. M. et al. Cancer metabolism, stemness and tumor recurrence: MCT1 and MCT4 are functional biomarkers of metabolic symbiosis in head and neck cancer. Cell Cycle 12, 1371–1384 (2013).
  CAS PubMed PubMed Central Google Scholar
• Wurm, C. A. et al. Nanoscale distribution of mitochondrial import receptor Tom20 is adjusted to cellular conditions and exhibits an inner-cellular gradient. Proc. Natl Acad. Sci. USA 108, 13546–13551 (2011).
  CAS PubMed PubMed Central Google Scholar
• Gehrke, S. et al. PINK1 and Parkin control localized translation of respiratory chain component mRNAs on mitochondria outer membrane. Cell Metab. 21, 95–108 (2015).
  CAS PubMed PubMed Central Google Scholar
• Vazquez, F. et al. PGC1α expression defines a subset of human melanoma tumors with increased mitochondrial capacity and resistance to oxidative stress. Cancer Cell 23, 287–301 (2013).
  CAS PubMed PubMed Central Google Scholar
• LeBleu, V. S. et al. PGC-1α mediates mitochondrial biogenesis and oxidative phosphorylation in cancer cells to promote metastasis. Nat. Cell Biol. 16, 992–1003 (2014).
  CAS PubMed PubMed Central Google Scholar
• Tan, A. S. et al. Mitochondrial genome acquisition restores respiratory function and tumorigenic potential of cancer cells without mitochondrial DNA. Cell Metab. 21, 81–94 (2015).
  CAS PubMed Google Scholar
• Katajisto, P. et al. Asymmetric apportioning of aged mitochondria between daughter cells is required for stemness. Science 348, 340–343 (2015).
  CAS PubMed PubMed Central Google Scholar
• Lamb, R. et al. Antibiotics that target mitochondria effectively eradicate cancer stem cells, across multiple tumor types: treating cancer like an infectious disease. Oncotarget 6, 4569–4584 (2015).
  PubMed PubMed Central Google Scholar
• Lamb, R. et al. Dissecting tumor metabolic heterogeneity: telomerase and large cell size metabolically define a sub-population of stem-like, mitochondrial-rich, cancer cells. Oncotarget 6, 21892–21905 (2015).
  PubMed PubMed Central Google Scholar
• Lo-Coco, F. et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N. Engl. J. Med. 369, 111–121 (2013).
  CAS PubMed Google Scholar
• Owen, M. R., Doran, E. & Halestrap, A. P. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem. J. 348, 607–614 (2000).
  CAS PubMed PubMed Central Google Scholar
• Pelicano, H. et al. Inhibition of mitochondrial respiration: a novel strategy to enhance drug-induced apoptosis in human leukemia cells by a reactive oxygen species-mediated mechanism. J. Biol. Chem. 278, 37832–37839 (2003).
  CAS PubMed Google Scholar
• Pollak, M. Overcoming drug development bottlenecks with repurposing: repurposing biguanides to target energy metabolism for cancer treatment. Nat. Med. 20, 591–593 (2014).
  CAS PubMed Google Scholar
• Bowker, S. L., Majumdar, S. R., Veugelers, P. & Johnson, J. A. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 29, 254–258 (2006).
  PubMed Google Scholar
• Hirsch, H. A., Iliopoulos, D., Tsichlis, P. N. & Struhl, K. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res. 69, 7507–7511 (2009).
  CAS PubMed PubMed Central Google Scholar
• Hadad, S. et al. Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial. Breast Cancer Res. Treat. 128, 783–794 (2011).
  CAS PubMed Google Scholar
• Menendez, J. A. et al. Metformin is synthetically lethal with glucose withdrawal in cancer cells. Cell Cycle 11, 2782–2792 (2012).
  CAS PubMed Google Scholar
• Birsoy, K. et al. Metabolic determinants of cancer cell sensitivity to glucose limitation and biguanides. Nature 508, 108–112 (2014).
  CAS PubMed PubMed Central Google Scholar
• Chen, G., Xu, S., Renko, K. & Derwahl, M. Metformin inhibits growth of thyroid carcinoma cells, suppresses self-renewal of derived cancer stem cells, and potentiates the effect of chemotherapeutic agents. J. Clin. Endocrinol. Metab. 97, E510–E520 (2012).
  CAS PubMed Google Scholar
• Song, C. W. et al. Metformin kills and radiosensitizes cancer cells and preferentially kills cancer stem cells. Sci. Rep. 2, 362 (2012).
  PubMed PubMed Central Google Scholar
• Bao, B. et al. Metformin inhibits cell proliferation, migration and invasion by attenuating CSC function mediated by deregulating miRNAs in pancreatic cancer cells. Cancer Prev. Res. (Phila.) 5, 355–364 (2012).
  CAS Google Scholar
• Foretz, M., Guigas, B., Bertrand, L., Pollak, M. & Viollet, B. Metformin: from mechanisms of action to therapies. Cell Metab. 20, 953–966 (2014).
  CAS PubMed Google Scholar
• Kordes, S. et al. Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial. Lancet Oncol. 16, 839–847 (2015).
  CAS PubMed Google Scholar
• Salani, B. et al. Metformin, cancer and glucose metabolism. Endocr. Relat. Cancer 21, R461–R471 (2014).
  PubMed Google Scholar
• Britten, C. D. et al. A phase I and pharmacokinetic study of the mitochondrial-specific rhodacyanine dye analog MKT 077. Clin. Cancer Res. 6, 42–49 (2000).
  CAS PubMed Google Scholar
• Propper, D. J. et al. Phase I trial of the selective mitochondrial toxin MKT077 in chemo-resistant solid tumours. Ann. Oncol. 10, 923–927 (1999).
  CAS PubMed Google Scholar
• Michelakis, E. D., Webster, L. & Mackey, J. R. Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer. Br. J. Cancer 99, 989–994 (2008).
  CAS PubMed PubMed Central Google Scholar
• Fu, X. et al. 2-hydroxyglutarate inhibits ATP synthase and mTOR signaling. Cell Metab. 22, 508–515 (2015).
  CAS PubMed PubMed Central Google Scholar
• Yan, H., Bigner, D. D., Velculescu, V. & Parsons, D. W. Mutant metabolic enzymes are at the origin of gliomas. Cancer Res. 69, 9157–9159 (2009).
  CAS PubMed PubMed Central Google Scholar
• Fathi, A. T., Wander, S. A., Faramand, R. & Emadi, A. Biochemical, epigenetic and metabolic approaches to target IDH mutations in acute myeloid leukemia. Semin Hematol. 52, 165–171 (2015).
  CAS PubMed Google Scholar
• Sagan, L. On the origin of mitosing cells. J. Theor. Biol. 14, 255–274 (1967).
  CAS PubMed Google Scholar
• Beckmann, R. & Herrmann, J. M. Mitoribosome oddities. Science 348, 288–289 (2015).
  CAS PubMed Google Scholar
• Greber, B. J. et al. The complete structure of the 55S mammalian mitochondrial ribosome. Science 348, 303–308 (2015).
  CAS PubMed Google Scholar
• Amunts, A., Brown, A., Toots, J., Scheres, S. H. & Ramakrishnan, V. The structure of the human mitochondrial ribosome. Science 348, 95–98 (2015).
  CAS PubMed PubMed Central Google Scholar
• Amunts, A. et al. Structure of the yeast mitochondrial large ribosomal subunit. Science 343, 1485–1489 (2014).
  CAS PubMed PubMed Central Google Scholar
• Brown, A. et al. Structure of the large ribosomal subunit from human mitochondria. Science 346, 718–722 (2014).
  CAS PubMed PubMed Central Google Scholar
• Wilson, D. N. Ribosome-targeting antibiotics and mechanisms of bacterial resistance. Nat. Rev. Microbiol. 12, 35–48 (2014).
  CAS PubMed Google Scholar
• Carter, A. P. et al. Functional insights from the structure of the 30S ribosomal subunit and its interactions with antibiotics. Nature 407, 340–348 (2000).
  CAS PubMed Google Scholar
• Moazed, D. & Noller, H. F. Interaction of antibiotics with functional sites in 16S ribosomal RNA. Nature 327, 389–394 (1987).
  CAS PubMed Google Scholar
• Greber, B. J. & Ban, N. Structure and function of the mitochondrial ribosome. Annu. Rev. Biochem. http://dx.doi.org/10.1146/annurevbiochem060815014343 (2016).
• Prezant, T. R. et al. Mitochondrial ribosomal RNA mutation associated with both antibiotic-induced and non-syndromic deafness. Nat. Genet. 4, 289–294 (1993).
  CAS PubMed Google Scholar
• Bitner-Glindzicz, M. et al. Prevalence of mitochondrial 1555A→G mutation in European children. N. Engl. J. Med. 360, 640–642 (2009).
  PubMed Google Scholar
• Soriano, A., Miro, O. & Mensa, J. Mitochondrial toxicity associated with linezolid. N. Engl. J. Med. 353, 2305–2306 (2005).
  CAS PubMed Google Scholar
• Ferreri, A. J. et al. Bacteria-eradicating therapy with doxycycline in ocular adnexal MALT lymphoma: a multicenter prospective trial. J. Natl Cancer Inst. 98, 1375–1382 (2006).
  CAS PubMed Google Scholar
• Ferreri, A. J. et al. Chlamydophila psittaci eradication with doxycycline as first-line targeted therapy for ocular adnexae lymphoma: final results of an international phase II trial. J. Clin. Oncol. 30, 2988–2994 (2012).
  CAS PubMed Google Scholar
• Skrtic, M. et al. Inhibition of mitochondrial translation as a therapeutic strategy for human acute myeloid leukemia. Cancer Cell 20, 674–688 (2011).
  CAS PubMed PubMed Central Google Scholar
• Bahrami, F., Morris, D. L. & Pourgholami, M. H. Tetracyclines: drugs with huge therapeutic potential. Mini Rev. Med. Chem. 12, 44–52 (2012).
  CAS PubMed Google Scholar
• Yang, M., Soga, T. & Pollard, P. J. Oncometabolites: linking altered metabolism with cancer. J. Clin. Invest. 123, 3652–3658 (2013).
  CAS PubMed PubMed Central Google Scholar
• Vazquez, A., Liu, J., Zhou, Y. & Oltvai, Z. N. Catabolic efficiency of aerobic glycolysis: the Warburg effect revisited. BMC Syst. Biol. 4, 58 (2010).
  PubMed PubMed Central Google Scholar
• Shlomi, T., Benyamini, T., Gottlieb, E., Sharan, R. & Ruppin, E. Genome-scale metabolic modeling elucidates the role of proliferative adaptation in causing the Warburg effect. PLoS Comput. Biol. 7, e1002018 (2011).
  CAS PubMed PubMed Central Google Scholar
• Sena, L. A. & Chandel, N. S. Physiological roles of mitochondrial reactive oxygen species. Mol. Cell 48, 158–167 (2012).
  CAS PubMed PubMed Central Google Scholar
• Martinez-Outschoorn, U. E. et al. Oxidative stress in cancer associated fibroblasts drives tumor-stroma co-evolution: a new paradigm for understanding tumor metabolism, the field effect and genomic instability in cancer cells. Cell Cycle 9, 3256–3276 (2010).
  CAS PubMed PubMed Central Google Scholar
• Asterholm, I. W., Mundy, D. I., Weng, J., Anderson, R. G. & Scherer, P. E. Altered mitochondrial function and metabolic inflexibility associated with loss of caveolin-1. Cell Metab. 15, 171–185 (2012).
  PubMed PubMed Central Google Scholar
• Chen, J. L. et al. The genomic analysis of lactic acidosis and acidosis response in human cancers. PLoS Genet. 4, e1000293 (2008).
  PubMed PubMed Central Google Scholar
• Xie, J. et al. Beyond Warburg effect — dual metabolic nature of cancer cells. Sci. Rep. 4, 4927 (2014).
  PubMed PubMed Central Google Scholar
• Gorrini, C., Harris, I. S. & Mak, T. W. Modulation of oxidative stress as an anticancer strategy. Nat. Rev. Drug Discov. 12, 931–947 (2013).
  CAS PubMed Google Scholar
• Nisoli, E. et al. Mitochondrial biogenesis in mammals: the role of endogenous nitric oxide. Science 299, 896–899 (2003).
  CAS PubMed Google Scholar
• Nisoli, E. et al. Calorie restriction promotes mitochondrial biogenesis by inducing the expression of eNOS. Science 310, 314–317 (2005).
  CAS PubMed Google Scholar
• Hasmann, M. & Schemainda, I. FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis. Cancer Res. 63, 7436–7442 (2003).
  CAS PubMed Google Scholar
• Sampath, D., Zabka, T. S., Misner, D. L., O'Brien, T. & Dragovich, P. S. Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) as a therapeutic strategy in cancer. Pharmacol. Ther. 151, 16–31 (2015).
  CAS PubMed Google Scholar
• Burgos, E. S. NAMPT in regulated NAD biosynthesis and its pivotal role in human metabolism. Curr. Med. Chem. 18, 1947–1961 (2011).
  CAS PubMed Google Scholar
• Yun, J. et al. Vitamin C selectively kills KRAS and BRAF mutant colorectal cancer cells by targeting GAPDH. Science 350, 1391–1396 (2015).
  CAS PubMed PubMed Central Google Scholar
• Porporato, P. E. et al. A mitochondrial switch promotes tumor metastasis. Cell Rep. 8, 754–766 (2014).
  CAS PubMed Google Scholar
• DeNicola, G. M. et al. Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature 475, 106–109 (2011).
  CAS PubMed PubMed Central Google Scholar
• Wells, G. Peptide and small molecule inhibitors of the Keap1–Nrf2 protein–protein interaction. Biochem. Soc. Trans. 43, 674–679 (2015).
  CAS PubMed Google Scholar
• Wang, G. L., Jiang, B. H., Rue, E. A. & Semenza, G. L. Hypoxia-inducible factor 1 is a basic-helix-loop- helix-PAS heterodimer regulated by cellular O2 tension. Proc. Natl Acad. Sci. USA 92, 5510–5514 (1995).
  CAS PubMed PubMed Central Google Scholar
• Zhang, H. et al. HIF-1 inhibits mitochondrial biogenesis and cellular respiration in VHL-deficient renal cell carcinoma by repression of C-MYC activity. Cancer Cell 11, 407–420 (2007).
  CAS PubMed Google Scholar
• Kim, J. W., Gao, P., Liu, Y. C., Semenza, G. L. & Dang, C. V. Hypoxia-inducible factor 1 and dysregulated c-Myc cooperatively induce vascular endothelial growth factor and metabolic switches hexokinase 2 and pyruvate dehydrogenase kinase 1. Mol. Cell. Biol. 27, 7381–7393 (2007).
  CAS PubMed PubMed Central Google Scholar
• Luo, W. et al. Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1. Cell 145, 732–744 (2011).
  CAS PubMed PubMed Central Google Scholar
• Fukuda, R. et al. HIF-1 regulates cytochrome oxidase subunits to optimize efficiency of respiration in hypoxic cells. Cell 129, 111–122 (2007).
  CAS PubMed Google Scholar
• Zhang, H. et al. Mitochondrial autophagy is an HIF-1-dependent adaptive metabolic response to hypoxia. J. Biol. Chem. 283, 10892–10903 (2008).
  CAS PubMed PubMed Central Google Scholar
• Semenza, G. L. HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations. J. Clin. Invest. 123, 3664–3671 (2013).
  CAS PubMed PubMed Central Google Scholar
• Velasco-Hernandez, T., Hyrenius-Wittsten, A., Rehn, M., Bryder, D. & Cammenga, J. HIF-1α can act as a tumor suppressor gene in murine acute myeloid leukemia. Blood 124, 3597–3607 (2014).
  CAS PubMed Google Scholar
• Chiavarina, B. et al. HIF1-alpha functions as a tumor promoter in cancer associated fibroblasts, and as a tumor suppressor in breast cancer cells: autophagy drives compartment-specific oncogenesis. Cell Cycle 9, 3534–3551 (2010).
  CAS PubMed PubMed Central Google Scholar
• Wilson, W. R. & Hay, M. P. Targeting hypoxia in cancer therapy. Nat. Rev. Cancer 11, 393–410 (2011).
  CAS PubMed Google Scholar
• Talekar, M., Boreddy, S. R., Singh, A. & Amiji, M. Tumor aerobic glycolysis: new insights into therapeutic strategies with targeted delivery. Expert Opin. Biol. Ther. 14, 1145–1159 (2014).
  CAS PubMed Google Scholar
• Chen, B. J., Wu, Y. L., Tanaka, Y. & Zhang, W. Small molecules targeting c-Myc oncogene: promising anti-cancer therapeutics. Int. J. Biol. Sci. 10, 1084–1096 (2014).
  PubMed PubMed Central Google Scholar
• Yuneva, M. O. et al. The metabolic profile of tumors depends on both the responsible genetic lesion and tissue type. Cell Metab. 15, 157–170 (2012).
  CAS PubMed PubMed Central Google Scholar
• Valencia, T. et al. Metabolic reprogramming of stromal fibroblasts through p62–mTORC1 signaling promotes inflammation and tumorigenesis. Cancer Cell 26, 121–135 (2014).
  CAS PubMed PubMed Central Google Scholar
• Amend, S. R. & Pienta, K. J. Ecology meets cancer biology: the cancer swamp promotes the lethal cancer phenotype. Oncotarget 6, 9669–9678 (2015).
  PubMed PubMed Central Google Scholar
• Draoui, N. & Feron, O. Lactate shuttles at a glance: from physiological paradigms to anti-cancer treatments. Dis. Model. Mech. 4, 727–732 (2011).
  CAS PubMed PubMed Central Google Scholar
• White, E. Deconvoluting the context-dependent role for autophagy in cancer. Nat. Rev. Cancer 12, 401–410 (2012).
  CAS PubMed PubMed Central Google Scholar
• Martinez-Outschoorn, U. E. et al. Autophagy in cancer associated fibroblasts promotes tumor cell survival: role of hypoxia, HIF1 induction and NFκB activation in the tumor stromal microenvironment. Cell Cycle 9, 3515–3533 (2010).
  CAS PubMed PubMed Central Google Scholar
• Takeuchi, H. et al. Synergistic augmentation of rapamycin-induced autophagy in malignant glioma cells by phosphatidylinositol 3-kinase/protein kinase B inhibitors. Cancer Res. 65, 3336–3346 (2005).
  CAS PubMed Google Scholar
• Chiarini, F., Evangelisti, C., McCubrey, J. A. & Martelli, A. M. Current treatment strategies for inhibiting mTOR in cancer. Trends Pharmacol. Sci. 36, 124–135 (2015).
  CAS PubMed Google Scholar
• Kimura, T., Takabatake, Y., Takahashi, A. & Isaka, Y. Chloroquine in cancer therapy: a double-edged sword of autophagy. Cancer Res. 73, 3–7 (2013).
  CAS PubMed Google Scholar
• Farber, S. & Diamond, L. K. Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid. N. Engl. J. Med. 238, 787–793 (1948).
  CAS PubMed Google Scholar
• Visentin, M., Zhao, R. & Goldman, I. D. The antifolates. Hematol. Oncol. Clin. North Am. 26, 629–648 (2012).
  PubMed PubMed Central Google Scholar
• Kaelin, W. G. Jr & McKnight, S. L. Influence of metabolism on epigenetics and disease. Cell 153, 56–69 (2013).
  CAS PubMed PubMed Central Google Scholar
• Ye, D., Ma, S., Xiong, Y. & Guan, K. L. _R_-2-hydroxyglutarate as the key effector of IDH mutations promoting oncogenesis. Cancer Cell 23, 274–276 (2013).
  CAS PubMed PubMed Central Google Scholar
• Dang, L. et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462, 739–744 (2009).
  CAS PubMed PubMed Central Google Scholar
• Losman, J. A. et al. (R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible. Science 339, 1621–1625 (2013).
  CAS PubMed Google Scholar
• Rohle, D. et al. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science 340, 626–630 (2013).
  CAS PubMed PubMed Central Google Scholar
• Smolkova, K., Dvorak, A., Zelenka, J., Vitek, L. & Jezek, P. Reductive carboxylation and 2-hydroxyglutarate formation by wild-type IDH2 in breast carcinoma cells. Int. J. Biochem. Cell Biol. 65, 125–133 (2015).
  CAS PubMed Google Scholar
• Intlekofer, A. M. et al. Hypoxia induces production of L-2-hydroxyglutarate. Cell Metab. 22, 304–311 (2015).
  CAS PubMed PubMed Central Google Scholar
• Carrer, A. & Wellen, K. E. Metabolism and epigenetics: a link cancer cells exploit. Curr. Opin. Biotechnol. 34, 23–29 (2015).
  CAS PubMed Google Scholar
• Peiris-Pages, M., Martinez-Outschoorn, U. E., Sotgia, F. & Lisanti, M. P. Metastasis and oxidative stress: are antioxidants a metabolic driver of progression? Cell Metab. 22, 956–958 (2015).
  CAS PubMed Google Scholar
• Clem, B. F. et al. Targeting 6-phosphofructo-2-kinase (PFKFB3) as a therapeutic strategy against cancer. Mol. Cancer Ther. 12, 1461–1470 (2013).
  CAS PubMed PubMed Central Google Scholar
• Morais-Santos, F. et al. Targeting lactate transport suppresses in vivo breast tumour growth. Oncotarget 6, 19177–19189 (2015).
  PubMed PubMed Central Google Scholar
• Fujiwara, S. et al. PDK1 inhibition is a novel therapeutic target in multiple myeloma. Br. J. Cancer 108, 170–178 (2013).
  CAS PubMed Google Scholar
• Sellers, K. et al. Pyruvate carboxylase is critical for non-small-cell lung cancer proliferation. J. Clin. Invest. 125, 687–698 (2015).
  PubMed PubMed Central Google Scholar
• Pardee, T. S. et al. A phase I study of the first-in-class antimitochondrial metabolism agent, CPI-613, in patients with advanced hematologic malignancies. Clin. Cancer Res. 20, 5255–5264 (2014).
  CAS PubMed PubMed Central Google Scholar
• Wang, F. et al. Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. Science 340, 622–626 (2013).
  CAS PubMed Google Scholar
• El-Mir, M. Y. et al. Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J. Biol. Chem. 275, 223–228 (2000).
  CAS PubMed Google Scholar
• Jara, J. A. & Lopez-Munoz, R. Metformin and cancer: between the bioenergetic disturbances and the antifolate activity. Pharmacol. Res. 101, 102–108 (2015).
  CAS PubMed Google Scholar
• Hitosugi, T. et al. Phosphoglycerate mutase 1 coordinates glycolysis and biosynthesis to promote tumor growth. Cancer Cell 22, 585–600 (2012).
  CAS PubMed PubMed Central Google Scholar
• Feun, L. G., Kuo, M. T. & Savaraj, N. Arginine deprivation in cancer therapy. Curr. Opin. Clin. Nutr. Metab. Care 18, 78–82 (2015).
  CAS PubMed Google Scholar
• Lamb, R. et al. Doxycycline down-regulates DNA-PK and radiosensitizes tumor initiating cells: implications for more effective radiation therapy. Oncotarget 6, 14005–14025 (2015).
  PubMed PubMed Central Google Scholar
• Pham, E. et al. Translational impact of nanoparticle-drug conjugate CRLX101 with or without bevacizumab in advanced ovarian cancer. Clin. Cancer Res. 21, 808–818 (2015).
  CAS PubMed Google Scholar
• Galluzzi, L. et al. Autophagy in malignant transformation and cancer progression. EMBO J. 34, 856–880 (2015).
  CAS PubMed PubMed Central Google Scholar
• Zadra, G., Batista, J. L. & Loda, M. Dissecting the dual role of AMPK in cancer: from experimental to human studies. Mol. Cancer Res. 13, 1059–1072 (2015).
  CAS PubMed PubMed Central Google Scholar
• Sayin, V. I. et al. Antioxidants accelerate lung cancer progression in mice. Sci. Transl. Med. 6, 221ra215 (2014).
  Google Scholar
• Pavlides, S. et al. Warburg meets autophagy: cancer-associated fibroblasts accelerate tumor growth and metastasis via oxidative stress, mitophagy, and aerobic glycolysis. Antioxid. Redox Signal. 16, 1264–1284 (2012).
  CAS PubMed PubMed Central Google Scholar